GPCR drugs may limit myocardial injury

Monash University researchers believe they have found a way to reduce myocardial damage after a heart attack without the dangerous side effects of adenosine A1 receptor drugs.

Professors Arthur Christopoulos and colleagues at the Monash Institute of Pharmaceutical Sciences have used molecular pharmacology and medicinal chemistry techniques to investigate a specific protein belonging to the family of G protein-coupled receptors (GPCRs).